注册以创建品种、
财经事件和所关注作者内容的提醒
免费注册 已有账户? 登录
Caribou Biosciences Inc是一家临床阶段基因组编辑生物制药公司。该公司正在为患有毁灭性疾病的患者开发具有变革性的聚集性定期间隔短回文重复序列(CRISPR)疗法。该公司的CRISPR平台CRISPR hybrid RNA-DNA(chRDNA)能够实现卓越的基因组编辑精度,以开发专门设计用于增强持久性的细胞疗法。它正在推进一系列异基因或现成的嵌合抗原受体(CAR)-T(CAR-T)和CAR自然杀伤(CAR-NK)细胞疗法,用于治疗血液系统恶性肿瘤和实体瘤患者。其主要候选产品CB-010是一种临床阶段异基因抗CD19 CAR-T细胞疗法,通过对PDCDI基因进行基因组编辑敲除,从CAR-T细胞表面去除程序性细胞死亡蛋白1(PD-1)。该公司的候选产品还包括CB-011、CB-012和CB-012。
名称 | 年龄 | 任期 | 标题 |
---|---|---|---|
Rachel E. Haurwitz | 36 | 2011 | Co-Founder, CEO, President & Director |
Martin Jinek | - | - | Member of Scientific Advisory Board |
Andrew L. Guggenhime | 54 | 2021 | Independent Chairman |
Katy Rezvani | - | - | Member of Scientific Advisory Board |
Scott N. Braunstein | 59 | 2021 | Independent Director |
Jennifer A. Doudna | 58 | - | Member of Scientific Advisory Board |
Cameron J. Turtle | - | - | Member of Scientific Advisory Board |
Natalie R. Sacks | 57 | 2018 | Independent Director |
Noopur Raje | - | - | Member of Scientific Advisory Board |
Dara Richardson-Heron | 59 | 2021 | Independent Director |
Ami Bhatt | - | - | Member of Scientific Advisory Board |
Ran Zheng | 59 | 2021 | Independent Director |
Nancy Whiting | 50 | 2021 | Independent Director |
David Lee Johnson | 54 | 2022 | Independent Director |
Stephen J. Schuster | - | 2023 | Member of Scientific Advisory Board |
Sundar Jagannath | - | 2023 | Member of Scientific Advisory Board |
Akos Czibere | - | 2024 | Member of Scientific Advisory Board |
确定屏蔽%USER_NAME%?
如果屏蔽,您和%USER_NAME%都无法看到相互在Investing.com上发布的信息。
%USER_NAME%已成功添加至屏蔽列表
由于您刚刚取消屏蔽此人,因此必须等待48小时才能重新屏蔽。
您举报该评论的原因为:
谢谢您!
您的举报将会被发送到管理员进行审核